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Background: Autoantibodies against aminoacyl-tRNA synthetases (ARS) have been found to be
highly specific for polymyositis and dermatomyositis (PM/DM) and to correlate strongly with
complicating interstitial pneumonia (IP). The aim of the present study was to compare the clin-
ical presentations of anti-ARS antibody-positive IP patients with or without manifestations of
PM/DM.
Methods: We retrospectively examined 36 IP patients with anti-ARS antibodies. Sixteen
patients presented with and 20 without the features of PM/DM. They were divided into PM/
DM-IP and idiopathic-IP (IIP) groups. Clinical symptoms, findings on physical examination, labo-
ratory data, pulmonary function, computed tomography (CT), and bronchoalveolar lavage fluid
(BALF) cell counts were compared.
Results: Skin findings, myalgia, and elevation of serum creatinine kinase were found in the PM/
DM-IP group. Features common to both groups included: volume loss in lower bilateral lobes;
ground-glass opacities, reticular shadows and traction bronchiectasis on chest CT; high
percentage of lymphocytes (IIP: 44.0%  21.0% (mean  SD), PM/DM-IP: 50.5%  23.5%) and
low CD4/8 ratios (IIP: 0.36  0.34, PM/DM-IP: 0.44  0.42) in BALF; decreased pulmonary func-
tion, including percentage of predicted vital capacity (VC) (IIP: 80.1%  15.4%, PM/DM-IP:
73.6%  16.4%), residual volume (RV) (IIP: 70.7%  21.7%, PM/DM-IP: 71.5%  17.1%), total lungutoantibodies against aminoacyl-tRNA synthetases; PM/DM, polymyositis and dermatomyositis; IIP,
IP, fibrotic nonspecific interstitial pneumonia.
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Pulmonary manifestations of anti-ARS antibody 129capacity (TLC) (IIP: 73.4%  13.6%, PM/DM-IP: 71.6%  13.0%), and diffusing capacity DLco (IIP:
57.5%  26.7%, PM/DM-IP: 46.4%  10.3%). Both groups achieved good responses to initial corti-
costeroid or immunosuppressant therapy.
Conclusion: Patients with anti-ARS antibody-positive IP have common pulmonary manifesta-
tions regardless of the presence of PM/DM.
ª 2012 Published by Elsevier Ltd.Table 1 Types of anti-ARS antibodies.
IIP PM/DM-IP Total (%)
Jo-1 4 6 10 (27.8)
KS 2 1 3 (8.3)
OJ 2 0 2 (5.5)
PL-12 4 0 4 (11.1)
PL-7 3 1 4 (11.1)
EJ 5 8 13 (36.1)
Total 20 16 36
IIP group; women nZ 14, men nZ 6, (median age 63 yrs, range
21e72 yrs) PM/DM group; women n Z 12, men n Z 4, (median
age 60.5 yrs, range 43e69 yrs).Background
Autoantibodies against aminoacyl-tRNA synthetases (ARS),
a group of cytoplasmic enzymes, have been found to be
highly specific for polymyositis and dermatomyositis (PM/
DM), and to strongly correlate with complicating interstitial
pneumonia (IP). Eight anti-ARS autoantibodies have been
identified. These include anti-Jo-1, anti-PL-7, anti-PL-12,
anti-OJ, anti-EJ, anti-KS, anti-Zo, and anti-Ha.1e3
Patients with anti-ARS antibodies often present with the
following features: myositis, IP, inflammatory arthritis,
Raynaud’s phenomenon, mechanic’s hands, and fever.
These features and symptoms have been termed the
“antisynthetase syndrome”. However, some cases of IP
with anti-ARS-antibody have no symptoms of myositis.
Yoshimizu et al. have reported that there are common
clinical and pathological findings and computed tomog-
raphy (CT) findings in patients with interstitial lung disease
and anti-ARS antibodies.4 We conducted a retrospective,
observational study to compare the clinical features of
anti-ARS antibody-positive patients with either idiopathic
IP (IIP) or with PM/DM-associated IP (PM/DM-IP).
Patients and methods
We identified 36 anti-ARS-antibody-positive patients with IP
at Kanazawa University Hospital and our related facilities
from January 2005 to December 2010. The patients in the
present study are all Japanese. Anti-ARS antibody analysis
was performed at the Department of Dermatology in
Kanazawa University Hospital by immunoprecipitation using
35S-methionine-labeled extracts of K562 cells.
The patients were divided into 2 groups, those with and
without the features of PM/DM. There were 16 patients
with the features of PM/DM, and their IP was designated as
PM/DM-IP. The remaining 20 patients did not have any
features of collagen vascular diseases, and their IP was
designated as IIP. There were 14 women and 6 men in the
IIP group (mean  SD age at onset was 59.1  13.0 years;
range, 21e72 years), and 12 women and 4 men in the PM/
DM-IP group (mean  SD age at onset was 58.5  7.9 years;
range, 43e69 years). One woman in the PM/DM-IP group
also had systemic scleroderma. We extracted and evalu-
ated the following from the patients’ medical records:
clinical symptoms, physical examination, laboratory data,
pulmonary function tests, CT findings, and bronchoalveolar
lavage fluid (BALF) cell counts. Two pulmonologist (at least)
and one radiologist examined the chest CT scan. Bron-
choalveolar lavage was performed with 50 ml of saline for 3
times at the same site where bronchoscope was wedged.
We analyzed cell differentiation of the third fraction by
counting at least 300 cells on a smear prepared witha cytospin and WrighteGiemsa staining. Skin symptoms
such as eruptions, nailfold bleeding, Gottron papules,
mechanic’s hands, and heliotrope rash were diagnosed by
dermatologists specializing in collagen vascular diseases.
Statistical analysis
Variables are expressed as the mean  SD unless otherwise
stated. To detect differences between groups, Student’s t-
test was used for parametric data and the c2 square test
was employed for categorical data. Analyses were per-
formed using a statistical software package (StatView; SAS
Institute Inc; Cary, NC). A P-value <0.05 was considered to
be statistically significant.
Results
The types of anti-ARS antibodies detected are shown in
Table 1. Anti-Jo-1 antibody was detected in 10 patients
(27.8%), anti-KS in 3 patients (8.3%), anti-OJ in 2 patients
(5.5%), anti-PL-12 in 4 patients (11.1%), anti-PL-7 in 4
patients (11.1%), and anti-EJ in 13 patients (36.1%).
Table 2A shows the clinical symptoms of each patient
group. Nonproductive cough and dyspnea on exertion were
frequently seen in both groups. Fever was noticed in 3 (16%)
IIP patients and 7 (47%) PM/DM-IP patients (P < 0.05).
Myalgia was seen in 7 (47%) PM/DM-IP patients but was not
seen in the IIP patients (P < 0.05). Arthralgia was seen in 1
(5%) IIP patient and 3 (20%) PM/DM-IP patients. Raynaud’s
phenomenon was seen in 4 (21%) IIP patients and 2 (13%)
PM/DM-IP patients. Fever and myalgia were more
frequently investigated in the PM/DM-IP group than in the
IIP group (P < 0.05).
Table 2B summarizes the findings on physical examina-
tion. Erythema and heliotrope were seen only in the PM/
Table 2A Clinical symptoms.
IIP (n Z 19) PM/DM-IP (n Z 15)
Number (%) Number (%)
Fever 3 (16) 7 (47)a
Dry cough 14 (74) 9 (60)
Dyspnea 13 (68) 10 (67)
Myalgia 0 (0) 7 (47)a
Altheralgia 1 (5) 3 (20)
Raynaud 4 (21) 2 13
a p Value <0.05 (by c2 square test).
Table 2C Chest CT findings.
IIP (n Z 18) PM/DM-IP (n Z 13)
Number (%) Number (%)
LL-predominant 18 (100) 13 (100)
Peripheral-predominant 15 (83) 12 (92.3)
Reticular shadows 18 (100) 13 (100)
GGO 17 (94) 12 (92.3)
Consolidation 9 (50) 4 (30.7)
Peri-BVB shadows 12 (67) 11 (84.6)
Traction bronchiectasis 17 (94) 11 (84.6)
Honeycomb 1 (6) 0 (0)
Mediastinal LN swellings 1 (6) 1 (7.6)
Table 3A Laboratory data (mean  SD).
IIP (n Z 20) PM/DM-IP (n Z 16)
KL-6 (U/ml) 1342  794.6 1956  2395
SP-D (ng/ml) 226.2  41.7 245.4  193.0
SP-A (ng/ml) 81.2  41.7 86.8  60.7
WBC (103 ml) 8364  3910 10264  3243
CRP (mg/dl) 0.7  0.7 1.58  2.0
CK (IU/l) 87.7  40.1 1350  2238a
PaO2 (Torr) 76.3  12.1 77.9  13.3
A-aDO2 (Torr) 21.5  11.0 23.1  13.9
a p Value <0.05.
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DM-IP patients and 2 (11%) IIP patients. Gottron papules
were seen in 5 (31.3%) PM/DM-IP patients and 1 (5%) IIP
patient. Mechanic’s hands were detected in 2 (11%) IIP
patients and 5 (31.3%) PM/DM-IP patients.
Inspiratory fine crackles on auscultation of the chest
were heard in every patient, but no patient had clubbed
fingers. Erythema, nailfold bleeding, and Gottron papules
were significantly (P < 0.05) more frequent in the PM/DM-IP
group than in the IIP group.
Table 2C shows the CT findings. Lower lobe and periph-
eral predominant shadows, reticular shadows, ground-glass
opacities, and traction bronchiectasis were seen in almost
all the patients of both groups. Peribronchovascular candle
shadows were detected in more than half of the cases of
both groups. Honeycombing was seen only in the 1 patient
with scleroderma. One patient in each group had medias-
tinal lymph node swelling.
Common features of chest CT were seen in both groups.
We classified the CT findings in patients with IP as fibrotic
nonspecific interstitial pneumonia (fNSIP) patterns except
for 1 patient with definite honeycombing, whose findings
were classified as an interstitial pneumonia fibrosis (IPF)
pattern.
Table 3A shows the results of laboratory examinations at
diagnosis. Data (Tables 3Ae3C) are expressed as
mean  standard deviation. The serum KL-6, SP-D, SP-A,
the white blood cell count (WBC) and the serum CRP
levels of both groups were elevated, and the room-air PaO2
was slightly decreased and A-aDO2 was increased in bothTable 2B Physical examinations.
IIP (n Z 19) PM/DM-IP (n Z 16)
Number (%) Number (%)
Erythema 0 (0) 11 (68.8)a
Nailfold bleeding 2 (11) 7 (43.8)a
Gottron papules 1 (5) 5 (31.3)a
Heliotrope 0 (0) 2 (12.5)
Clubbed finger 0 (0) 0 (0)
Fine crackles 19 (100) 16 (100)
Mechanic’s hand 2 (11) 5 (31.3)
a p Value <0.05 (by c2 square test).groups (PaO2: 76.3  12.1 and 77.9  13.3 Torr; A-aDO2:
21.5  11.0 and 23.1  13.9 Torr; respectively, for IIP and
PM/DM-IP), which were not significantly different. These
values tended to be elevated in the PM/DM-IP group, but
there were no significant differences between the 2 groups.
The serum creatinine kinase was significantly (P < 0.05)
elevated in the PM/DM-IP group at 1350  2238 IU/l vs.
87.7  40.1 IU/l in the IIP group.
Table 3B shows the results of pulmonary function
testing. Vital capacity (VC), expressed as percentage of
the predicted value, was at the lower limit for normal for
both groups, and residual volume (RV), total lung capacity
(TLC) and lung carbon monoxide diffusing capacity DLco
were decreased in both groups. No obstructive ventilatoryTable 3B Pulmonary function tests.
IIP (n Z 20) PM/DM-IP (n Z 16)
VC (% pred.) 80.1  15.4 73.6  16.4
FEV1/FVC (%) 78.7  20.2 77.1  14.6
RV (% pred.) 70.7  21.7 71.5  17.1
TLC (%) 73.4  13.6 71.6  13.0
RV/TLC (%) 33.8  9.1 34.7  6.0
DLco (% pred.) 57.5  26.7 46.4  10.3
DLco/VA (% pred.) 88.4  25.3 77.2  12.8
% pred.: predicted percentage.
Table 3C Bronchoalveolar lavage fluid cell counts.
IIP (n Z 15) PM/DM-IP (n Z 13)
TCC (105/mL) 3.4  1.7 3.4  2.0
Macro (%) 44.8  21.0 36.3  25.0
Lym (%) 44.0  22.6 50.5  23.5
Neu (%) 8.6  10.0 8.9  6.3
Eo (%) 2.2  5.6 4.4  4.3
CD4/8 0.36  0.34 0.44  0.42
TCC: total cell count, Mac: macrophage, Lym: lymphocyte, Neu:
neutrophil, Eo: eosinophil.
Pulmonary manifestations of anti-ARS antibody 131disorders were seen in either group. The values for DLco/
alveolar volume (VA) were almost normal. There were no
significant differences in the values for pulmonary
function.
Table 3C shows results of BALF differential cell counts.
BAL was undertaken in 17 IIP cases and in 13 PM/DM-IP
cases. Two IIP cases were excluded from analysis because
BAL was undertaken after the initiation of steroidFigure 1 Representative chest computed tomography (CT) findin
CT demonstrates bilateral ground-glass opacities and linear and retreatment. High percentages of lymphocytes and low CD4/8
ratios were seen. These values were not significantly
different.
Fig. 1 shows representative chest CTs from patients with
each type of anti-ARS antibody. Every chest CT showed
bilateral ground-glass opacities, linear and reticular
shadows in the lower lobes, predominantly subpleural.
Shadow characteristics were similar regardless of the type
of anti-ARS antibody detected in the patient.
Table 4 summarizes the treatments. Prednisolone (PSL)
treatment was started as the primary treatment in almost
all cases, and was effective in almost all cases at the
initiation of treatment. In some cases, however, lung
fibrosis worsened and immunosuppressant drugs were
added while PSL was tapered. In one PM/DM-IP patient who
had anti-Jo-1 antibody, PSL treatment was very effective,
and treatment could be completed and PSL could be
stopped. In another PM/DM-IP case with anti-EJ antibody,
who was treated with a pulse of methylprednisolone (mPSL-
p) and a pulse of cyclophosphamide (CY-p), her IP rapidly
worsened and she died despite intensive therapy. One
patient had concomitant lung cancer, and died without
initiation of corticosteroid therapy.gs for patients with different anti-ARS antibodies. Every chest
ticular shadows in the lower lobes, predominantly subpleural.
Table 4 Treatment.
PSL
only
PSL þ CYA
(or TAC)
mPSL-p þ PSL mPSL-p þ PSL
þ CYA
CY pulse þ PSL
þ CYA
None mPSL-p
þ CY pulse
Total
IIP 11 2 1 2 1 3 0 20
PM/DM-IP 8 4 1 1 1 0 1 16
PSL: prednisolone, mPSL-p: methylprednisolone pulse.
CYA: cyclosporin, CY: cyclophosphamide, TAC: tacrolimus.
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Interstitial pneumonia (IP) is a common and serious
complication of PM/DM, particularly in patients with anti-
ARS antibody. Anti-ARS antibodies are found in approxi-
mately 25%e35% of patients with PM/DM. Anti-Jo-1 anti-
body is the most frequent antibody identified in PM/DM
(15%e20%), followed by anti-PL-7 and anti-PL-12 (5%e
10%).3 In our study, patients with anti-EJ were the most
frequent, followed by patients with anti-Jo-1. The clinical
features of our patients were remarkably similar in patients
with anti-ARS antibody-positive IP, with or without PM/DM.
It is thought that pulmonary manifestations such as IP may
precede PM/DM symptoms if anti-ARS antibodies are
detected. Kalluri et al. reported that IP with PL-12 antibody
preceded manifestations of connective tissue disease in
sixteen out of thirty-one patients (53%).5 There is a report
of a patient with pulmonary fibrosis in whom anti-Jo-1
antibody preceded the diagnosis of PM diagnosis by 12
months.6 Patients with IP and anti-ARS antibodies but
without myositis have been noted since the 1980s.7e10
There was a previous report that 5 of 10 patients positive
for anti-ARS antibody without evidence of myositis were
responsive to therapy.11
We expected that elevated serum CK levels and
symptoms such as erythema and myalgia would
predominate in the PM/DM group. But in this study,
some patients in the IIP group also had fever and nail-
fold bleeding, although most patients in that group did
not have any apparent PM/DM symptoms. We found that
many patients achieved good responses to prednisolone
or immunosuppressive therapy. All patient’s CK levels
are normal in IIP group. Seven of 16 patient’s CK levels
are increased in PM/DM-IP group. They are decreased
and normalized after treatment in all these seven cases.
Skin findings were diagnosed and followed regularly by
dermatologist at Kanazawa University Hospital. Some
patients transferred, we can follow 16 of 20 patients in
IIP group (five cases of 16 have skin lesions), 15 of 16
patients (twelve case of the 15 have skin lesions) in DM/
PM-IP group. The skin lesions are improved in all cases
after treatment. However, some patients recurred
following dose reduction. Patients with anti-ARS anti-
bodies have chronic and mild IP4; however, some
patients have acute progressive respiratory failure.11
One woman with anti-PL-12-antibody-positive IIP had
scleroderma. The IP might have been associated with
scleroderma, and she was the only case with honey-
combing. She did not meet the criteria of PM/DM.It was reported that patients with anti-ARS antibody-
positive IP have common clinical and pathological
features.4 In that study, 14 patients with anti-ARS anti-
bodies were examined. They concluded their results indi-
cated that patients with ILD usually have a good response to
corticosteroid treatment, however some have a rapidly
worsening course and recurrence, despite therapy. They
had nonspecific interstitial pneumonia (NSIP) and/or orga-
nizing pneumonia (OP) patterns on chest CT, increase
lymphocyte in BALF in 7 of 11 patients, which are similar to
our findings. There were no significant differences in
pulmonary manifestations between the patients with IIP
and PM/DM-IP. In some patients, their IP worsened or their
muscles weakened when they were tapered off steroids,
which suggests that we need to observe patients carefully
with regard to the appearance of PM/DM symptoms during
follow-up.Conclusions
There were no significant differences in the pulmonary
manifestations of IP in patients with anti-ARS antibody,
whether or not PM/DM was evident. Patients with chronic
IP, especially with NSIP findings on CT, should be tested for
anti-ARS antibodies. Detection of antibodies is important
for estimating their clinical course.Conflict of interest statement
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